Other
Beijing Bethune Charitable Foundation
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 2
1(33.3%)
Phase 1
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT07522411Phase 1Not Yet Recruiting
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Role: collaborator
NCT07306663Phase 3Active Not Recruiting
Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study
Role: collaborator
NCT06239870Phase 2Unknown
Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Role: collaborator
All 3 trials loaded